In summary, 18 cases presented with p53 inactivation, assessed using the IHC assay, and the frequency of p53 inactivation in both the NEC and non-NEC components was identical, i.e., 76.2% (16/21). This evidence concerns the gene TP53 and neuroendocrine carcinoma.